ImClone System's finance-meister is jumping ship, the company announced. And no, it's not your imagination--Ana Stancic's departure will make ImClone the sixth biopharma company to lose its finance chief in recent months. There's also Pfizer (which announced its new CFO yesterday [1]), Wyeth, AstraZeneca, Amgen, and Merck.
Stancic's departure will follow the entrance of new ImClone CEO John Johnson [2], who starts Monday. The company has been getting by on interim chief execs--including a three-person executive committee, which took over last year--since 2005.
- read the report [3] from The Wall Street Journal
Related Articles:
Amgen CFO walks as challenges mount
Pfizer hires on the axe man [1]
Links:
[1] http://www.fiercepharma.com/story/pfizer-hires-axe-man/2007-08-23
[2] http://www.fiercebiotech.com/story/c-l-john-johnson-run-imclone/2007-08-15
[3] http://blogs.wsj.com/health/2007/08/23/another-drug-co-finance-chief-exits-sort-of/